Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05877859 · ClinicalTrials.gov registry record
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
A clinical trial of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Emory University.
- Recruiting
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT05877859: Recruiting study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by Emory University.
NCT05877859 is a study of Breast Cancer Stage II and Breast Cancer Stage III that is actively recruiting participants, run by Emory University. The registered enrollment target is 10 participants, below the 181-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05877859, a study of Breast Cancer Stage II and Breast Cancer Stage III, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing standard of care neoadjuvant chemo- immunotherapy.
Primary Outcome
The change in the cytokine milieu specifically IFN-γ, IFN-α, IL-6 and TGF-β in the blood during standard of care neoadjuvant chemo-immunotherapy and its association with pathologic complete response in the tissue
Conditions Studied
Study Locations (1)
Georgia
- Emory University/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2027-04-10 |
What NCT05877859 shows while recruiting
NCT05877859 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 181-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 0 interventions.
NCT05877859 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05877859 about?
NCT05877859 is a clinical study titled "Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab". This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing standard of care neoadjuvant chemo- immunotherapy.
What is the current status of trial NCT05877859?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2023-05-30. Estimated completion is 2027-04-10.
What conditions does trial NCT05877859 study?
This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive, Breast Cancer Triple Negative.
Who is sponsoring clinical trial NCT05877859?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05877859 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Stage II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05877859's enrollment target sits among peer trials
10 23rd of 22 the lowest of 22 other Breast Cancer Stage II trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Stage II trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
RECRUITING · Phase 2
-
Optimizing Surgical Decisions in Young Adults With Breast Cancer
RECRUITING · NA
-
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
RECRUITING · Phase 2
-
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI